Highlights on molecular targets in the management of COVID-19: Possible role of pharmacogenomics.
J Int Med Res
; 51(1): 3000605231153764, 2023 Jan.
Article
in English
| MEDLINE | ID: covidwho-2223990
ABSTRACT
By the end of 2022, there had been a reduction in new cases and deaths caused by coronavirus disease 2019 (COVID-19). At the same time, new variants of the severe acute respiratory syndrome coronavirus 2 virus were being discovered. Critically ill patients with COVID-19 have been found to have high serum levels of proinflammatory cytokines, especially interleukin (IL)-6. COVID-19-related mortality has been attributed in most cases to the cytokine storm caused by increased levels of inflammatory cytokines. Dexamethasone in low doses and immunomodulators such as IL-6 inhibitors are recommended to overcome the cytokine storm. This current narrative review highlights the place of other therapeutic choices such as proteasome inhibitors, protease inhibitors and nuclear factor kappa B inhibitors in the treatment of patients with COVID-19.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
Type of study:
Reviews
Topics:
Variants
Limits:
Humans
Language:
English
Journal:
J Int Med Res
Year:
2023
Document Type:
Article
Affiliation country:
03000605231153764
Similar
MEDLINE
...
LILACS
LIS